Gregory T. Everson

Dr. Gregory T. Everson

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
LSLeonard B. Seeff
Leonard B. Seeff
GEGregory T. Everson
Gregory T. Everson
TMTimothy R. Morgan
Timothy R. Morgan
TCTeresa M. Curto
Teresa M. Curto
WLWilliam M. Lee
William M. Lee
JDJules L. Dienstag
Jules L. Dienstag

1 February 2014 in Gastroenterology
Verified
Journal Article
Open access
PDF file
GEGregory T. Everson
Gregory T. Everson
KSKaren D. Sims
Karen D. Sims
MRMaribel Rodriguez-Torres
Maribel Rodriguez-Torres
CHChristophe Hézode
Christophe Hézode
ELEric Lawitz
Eric Lawitz
DGDavid F. Gardiner
David F. Gardiner
Background & Aims The combination of peginterferon and ribavirin with telaprevir or boceprevir is the standard treatment of hepatitis C virus (HCV) genotype 1 infection. However, these drugs are not well tolerated because of their side effects and suboptimal virologic responses. In a phase 2a, open-label study, we examined the safety and efficacy of an interferon-free, ribavirin-free regimen of direct-acting antivirals, comprising daclatasvir (an NS5A replication complex inhibitor), asunaprevir (an NS3 protease inhibitor), and BMS-791325 (a non-nucleoside NS5B inhibitor), in patients with chronic HCV infection. Methods We analyzed data from 66 treatment-naive patients with HCV genotype 1 infection without cirrhosis who were assigned randomly to groups given daclatasvir (60 mg, once daily), asunaprevir (200 mg, twice daily), and BMS-791325 (75 or 150 mg, twice daily) for 12 or 24 weeks. The primary end point was an HCV-RNA level less than 25 IU/mL at 12 weeks after treatment (sustained virologic response at 12 weeks [SVR12]). Results In 64 patients, HCV-RNA levels were less than 25 IU/mL by week 4 of treatment (including 48 of 49 patients with HCV genotype 1a infection and 45 of 46 patients with the non-CC interleukin 28B genotype). Sixty-one patients (92%) achieved SVR12, based on a modified intention-to-treat analysis. Virologic responses were similar between 12 and 24 weeks of treatment. During the study, 2 patients experienced viral breakthrough and 1 patient relapsed. There were no grade 3-4 increases in levels of alanine or aspartate aminotransferases or bilirubin; there were no deaths or discontinuations resulting from serious adverse events or adverse events related to the treatment regimen. The most common adverse events were headache, asthenia, and gastrointestinal symptoms. Conclusions In a phase 2a study, the all-oral, interferon-free, and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 was well tolerated and achieved high rates of SVR12 in patients with HCV genotype 1 infection. Further studies of this regimen are warranted. ClinicalTrials.gov, number NCT01455090.

1 March 2011 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
ALAnna S. Lok
Anna S. Lok
JEJames E. Everhart
James E. Everhart
EWElizabeth C. Wright
Elizabeth C. Wright
ABAdrian M. Di Bisceglie
Adrian M. Di Bisceglie
HKHae–Young Kim
Hae–Young Kim
TMTimothy R. Morgan
Timothy R. Morgan

21 April 2011 in Hepatology
Verified
Journal Article
Open access
PDF file
JDJules L. Dienstag
Jules L. Dienstag
MGMarc G. Ghany
Marc G. Ghany
TMTimothy R. Morgan
Timothy R. Morgan
ABAdrian M. Di Bisceglie
Adrian M. Di Bisceglie
HBHerbert L. Bonkovsky
Herbert L. Bonkovsky
JEJames E. Everhart
James E. Everhart
The incidence of liver disease progression among subjects with histologically advanced but compensated chronic hepatitis C is incomplete. The Hepatitis C Antiviral Long-term Treatment against Cirrhosis Trial was a randomized study of 3.5 years of maintenance peginterferon treatment on liver disease progression among patients who had not cleared virus on peginterferon and ribavirin therapy. Patients were followed subsequently off therapy. Because maintenance peginterferon treatment did not alter liver disease progression, we analyzed treated and control patients together. Among 1,050 subjects (60% advanced fibrosis, 40% cirrhosis), we determined the rate of progression to cirrhosis over 4 years and of clinical outcomes over 8 years. Among patients with fibrosis, the incidence of cirrhosis was 9.9% per year. Six hundred seventy-nine clinical outcomes occurred among 329 subjects. Initial clinical outcomes occurred more frequently among subjects with cirrhosis (7.5% per year) than subjects with fibrosis (3.3% per year) ( P < 0.0001). Child-Turcotte-Pugh (CTP) score ≥7 was the most common first outcome, followed by hepatocellular carcinoma. Following occurrence of a CTP score ≥7, the rate of subsequent events increased to 12.9% per year, including a death rate of 10% per year. Age and sex did not influence outcome rates. Baseline platelet count was a strong predictor of all clinical outcomes. During the 8 years of follow-up, death or liver transplantation occurred among 12.2% of patients with advanced fibrosis and 31.5% of those with cirrhosis. Conclusion: Among patients with advanced hepatitis C who failed peginterferon and ribavirin therapy, the rate of liver-related outcomes, including death and liver transplantation, is high, especially once the CTP score reaches at least 7. (Hepatology 2011)

13 February 2012 in Hepatology
Verified
Journal Article
Open access
PDF file
JKJennifer J. Kiser
Jennifer J. Kiser
JBJames R. Burton
James R. Burton
PAPeter L. Anderson
Peter L. Anderson
GEGregory T. Everson
Gregory T. Everson
Boceprevir (BOC) and telaprevir (TPV), when added to pegylated interferon and ribavirin for the treatment of chronic hepatitis C virus (HCV) infection, increase the rates of sustained virologic response in treatment-naïve persons to approximately 70%. Though these agents represent an important advance in the treatment of chronic HCV, they present new treatment challenges to the hepatology community. BOC and TPV are both substrates and inhibitors of the hepatic enzyme, cytochrome P450 3A, and the drug transporter, P-glycoprotein, which predisposes these agents to many drug interactions. Identification and appropriate management of potential drug interactions with TPV and BOC is critical for optimizing therapeutic outcomes during hepatitis C treatment. This review highlights the pharmacologic characteristics and drug-interaction potential of BOC and TPV and provides guidance on the management of drug interactions with these agents. (Hepatology 2012;)

28 July 2014 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
KOKim M. M Olthoff
Kim M. M Olthoff
JEJean C. c Emond
Jean C. c Emond
TSTempie H. Shearon
Tempie H. Shearon
GEGregory T. Everson
Gregory T. Everson
TBTalia B. Baker
Talia B. Baker
JEJames E. Everhart
James E. Everhart
Adult‐to‐adult living donors and recipients were studied to characterize patterns of liver growth and identify associated factors in a multicenter study. Three hundred and fifty donors and 353 recipients in the Adult‐to‐Adult Living Donor Liver Transplantation Cohort Study (A2ALL) receiving transplants between March 2003 and February 2010 were included. Potential predictors of 3‐month liver volume included total and standard liver volumes (TLV and SLV), Model for End‐Stage Liver Disease (MELD) score (in recipients), the remnant and graft size, remnant‐to‐donor and graft‐to‐recipient weight ratios (RDWR and GRWR), remnant/TLV, and graft/SLV. Among donors, 3‐month absolute growth was 676 ± 251 g (mean ± SD), and percentage reconstitution was 80% ± 13%. Among recipients, GRWR was 1.3% ± 0.4% (8 < 0.8%). Graft weight was 60% ± 13% of SLV. Three‐month absolute growth was 549 ± 267 g, and percentage reconstitution was 93% ± 18%. Predictors of greater 3‐month liver volume included larger patient size (donors and recipients), larger graft volume (recipients), and larger TLV (donors). Donors with the smallest remnant/TLV ratios had larger than expected growth but also had higher postoperative bilirubin and international normalized ratio at 7 and 30 days. In a combined donor‐recipient analysis, donors had smaller 3‐month liver volumes than recipients adjusted for patient size, remnant or graft volume, and TLV or SLV (P = 0.004). Recipient graft failure in the first 90 days was predicted by poor graft function at day 7 (HR = 4.50, P = 0.001) but not by GRWR or graft fraction (P > 0.90 for each). Both donors and recipients had rapid yet incomplete restoration of tissue mass in the first 3 months, and this confirmed previous reports. Recipients achieved a greater percentage of expected total volume. Patient size and recipient graft volume significantly influenced 3‐month volumes. Importantly, donor liver volume is a critical predictor of the rate of regeneration, and donor remnant fraction affects postresection function. Liver Transpl 21:79‐88, 2015. © 2014 AASLD.